🇺🇸 FDA
Patent

US 9101643

Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)

granted A61KA61K31/7088A61K31/7115

Quick answer

US patent 9101643 (Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/7088, A61K31/7115, A61K31/713, A61P